SHEN26 (ATY014) is a potent and orally active RdRp inhibitor, with an IC50 for SARS-CoV-2 is 1.36 μM. SHEN26 is a 5’-cyclohexanecarboxylate derivative of GS-441524 . SHEN26 inhibits viral nucleic acid synthesis to achieve antiviral effects. SHEN26 can be used for the research of coronavirus disease 2019 (COVID-19).
IC50 of SHEN26 (ATY014) against variants of beta and delta are 1.12 μM and 0.35 μM[1].
















